Market research
In.TO InMed Pharmaceuticals Inc
TO CAD Not available
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 34M
- P/E ratio
- Not available
- Analyst target
- 14.85
- Dividend yield
- 0.0%
- Beta
- 1.4
Profile
Instrument facts
- Exchange
- TO
- Currency
- CAD
- Sector
- Not available
- Industry
- Not available
- ISIN
- CA4576375022
- Market cap
- 34M
- P/E ratio
- Not available
- Analyst target
- 14.85
- Dividend yield
- 0.0%
- Beta
- 1.4
About
About InMed Pharmaceuticals Inc
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Research context
InMed Pharmaceuticals Inc appears in PyInvesting’s Toronto Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
0 comments
Sign in to join the In.TO discussion.
No comments yet
Start a focused discussion about In.TO.